Monthly Archives: September 2011

Marathon Walk Update–Day of

I will write more later. I’m exhausted. The good news is I finished the 26.2 miles just after 4 p.m.–about ten hours on the trail.

The better news is that they raised more than $7.5 million through today’s activities. Caring for Carcinoid raised over $30,000.

When I crossed the finish line, I raised my walking stick with two hands over my head and shouted victory. I did not immediately drop down dead. Someone on the team asked me to do it again so I could have a picture of it.  As soon as we had that shot–I’ll post it tomorrow on Facebook and it will eventually find its way here–the official photographer for D-F wanted it repeated a third time.

Many other things to say, but really too beat to go on at any greater length.

Two new articles in resources

There are two new posts on the Resources page. One connects to the transcript of today’s neuroendocrine tumor web chat on Oncolink which has a large quantity of useful information for patients and families.

The other is a link to the abstract of an article in the Journal of Nuclear Medicine on a radiological technique for identifying NETs. The full article requires you pay a fee or be a subscriber to JNM. The article is highly technical and will be of more use to doctors and radiologists than to laypeople.

Sunday is the Jimmy Fund Marathon Walk. I hope to have pictures and a report on that either Sunday or Monday night, depending on how well this 59 year old body recovers from the 26+ mile hike.

If you are going to be in the Boston area Sunday I hope to reach mile 13 by about 10 am- 10:30 am and reach the finish line by 3 pm. Come out and greet the walkers as they reach the top of Heartbreak Hill and head into Boston.

Southcoast Today Article on Marathon Walk

The link below will take you to an article on my Marathon Walk this Sunday.

http://www.southcoasttoday.com/apps/pbcs.dll/article?AID=/20110915/PUB03/109150361

Thank you.

Marathon Walk Update

I got a note from a former student earlier tonight. Today she is a neurologist at a hospital in the US. She has been reading about the work we are trying to do on neuroendocrine cancer and carcinoid syndrome. Today she encountered the disease in a patient. The story she told me reduced me to tears. The patient’s cancer has spread from the original site.

It brought back Jane’s last months all over again. It brought back for me how little we know about the disease, how few weapons we have to even slow it down, how little money we spend on trying to find a cure each year.

We probably spent as much on treating Jane in the last four months of her life as we spent doing research on the disease all of last year.

As of tonight, friends of Walking with Jane have raised $3830 in support of my Jimmy Fund Marathon Walk this Sunday. That puts me in second place on the Caring for Carcinoid team as we try to raise $25,000 for neuroendocrine cancer and carcinoid syndrome research at the Dana-Farber Cancer Institute.

The person in first place on our team has raised $4397. The person in third has raised $3450. The team is under $600 away from that $25,000 goal.

All those numbers sound impressive. But last year less than $2.5 million was raised and spent nationally for NEC research. That sounds like a lot of money until you realize that the National Cancer Institute alone spent over $5 billion on cancer research last year.

Please do not misunderstand me. I am truly grateful for every nickel people have donated to the cause of putting this disease down. I know the financial straits that many of you face. I know how fortunate I am to have the kinds of friends who are willing to open their wallets for this cause. I know how fortunate I am to have the kinds of friends who are as generous with their time as so many of you have been these past several months.

This site does not exist without you. The Facebook page (Facebook.com/walkingwithjane) does not exist without you. The t-shirts, the water bottles, the pins, the bracelets–do not exist without you. The over $11,300 we have raised together to fight cancer this year does not exist without you.

And I feel truly blessed whenever I think about those things we have done together so far. Those thoughts can pull me out of all but the very darkest moments–and even those truly dark moments are lightened by those thoughts.

But I also know how far we still have to go. While the news from the research front in recent days has given me hope, I know that none of that news really even hints at a cure. This is going to be a very long–and expensive–fight.

Those of you who have made donations of time and/or money, please accept my sincere gratitude.

Those of you who have not yet made a donation, if you can afford even a few dollars, please go to http://www.kintera.org/faf/donorReg/donorPledge.asp?ievent=449987&supId=331022955 today and make a donation or a pledge to my Marathon Walk. Every nickel donated to me or to the Caring for Carcinoid team will go to research at Dana-Farber into NEC and CS.

Let’s turn no chance into a fighting chance for those with advanced cases of this disease. And let’s turn managing the disease into a cure for those  diagnosed at the early stages.

 

Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented at CIRSE

No sooner do I say I will not do this often than two stories leap off the page at me. This article is much more technical, but reports on a trial of a method for slowing down NEC after it has metastasized to the liver–which is where Jane was when she was diagnosed.

This feels to me to be a very positive development. I hope those of you in the medical field will let me know if this is as promising as it looks in the PR piece.

Here is the link: http://www.marketwatch.com/story/positive-phase-2-trial-results-from-neuroendocrine-tumor-cohort-presented-at-cirse-2011-09-12

I will post both these stories to the Resources page as well as posting them here.

One good article deserves wide audience

I will not often use this space to highlight a specific link beyond saying we have added something new in the resources or calendar.

I make an exception for this article from a Canadian newspaper. While the focus is on a person with the pancreatic version of NEC that Steve Jobs has, the article does a really good job of pointing out how quickly this disease is growing–and distinguishing it from the erroneous idea that this is just another form of pancreatic cancer. It also makes clear that this cancer can appear anywhere–and is not limited to a specific organ.

The piece also talks about how difficult the disease is to diagnose. The piece claims that 90 percent of the time NEC is diagnosed as something else.

Here  is the link to the article: http://www.brantfordexpositor.ca/ArticleDisplay.aspx?e=3294399

Go read it. Then post your response to the forum.

One year ago today…

(Editor’s Note: Two new links were added to the Resources page today. Two new events are scheduled to be added to the calendar today.)

One year ago today, Jane and I made our first trip to the Dana-Farber Cancer Institute in Boston.

We had neen to the local clinic in Fall River already. We had learned about a drug trial, but the size of the tumors in her liver had excluded her. That rejection had put a chill in both of us: it said the disease was so far along that there wasn’t much hope.

But Jane was a fighter. She wasn’t going to give up. Nor was I. We were going to the best place on Earth for the cancer she had. We were meeting with someone who had done more than read about the disease somewhere.

We were terrified. We were terrified because we figured this would be the day the other shoe would drop—the day someone finally said to us, “Look, you have no chance. We found it too late. There is nothing we can do. You should just go home, put your affairs in order, say your good-byes, make yourself as comfortable as you can, and prepare for the end.”

Instead, we met Dr. Jennifer Chan, who was not yet Jen to either one of us, but who would become not only the best doctor we could have found, but the best friend we could have asked for.

Jen listened to Jane that day. My job was to take notes and ask the questions no one else thought of or that Jane could not bring herself to ask. We’d made a list. I ticked off each one as it was answered.

And then Jen made clear that she thought this was not a lost cause. But she wanted to have Jane’s heart checked because sometimes NEC damages the heart.

We went into that appointment convinced we had days—maybe weeks. We came away believing we had many months—and perhaps years. In fact, knowing the pace at which knowledge of everything grows these days, we both came away believing, for the first time in months, that there was a future in which Jane would beat this cancer—and that we would have a long and happy retirement together—just as we had always imagined.

Jane got her first injection of octreotide that afternoon. We knew it was not a cure. But we also knew it might slow the disease, give her her appetite back, and put the brakes on the diarrhea that was becoming increasingly debilitating.

When Jane asked me to stop to get something to eat on the way home because she was hungry  I wanted to dance into the restaurant. And when she finished her sandwich without complaint, we both practically floated home.

Three months to the day later, in a hospital room in the cardiac intensive care unit at Brigham & Women’s Hospital, Jane would wake up just long enough to hear Jen tell us that there was nothing more they could do than make Jane comfortable. Thirty-two hours later Jane would defeat her cancer in the only way she had left—by dying and taking it with her.

We learned a lot in those three months. We taught a lot in those three months. We made a lot of friends in those three months.

But I never want anyone else to learn those lessons or teach those lessons or make those friends in that way.

So this site exists; I make donations; I talk to whoever will listen; I take long walks wearing t-shirts I would never have worn before—all in the hope that through those actions there will come a day that we have a cure for this—so that for someone else out there there is a way to defeat this disease without dying and taking it with them.

Webchat on Friday September 16

Focus on Neuroendocrine Tumors Webchat

Public Event

 

http://tinyurl.com/3u6c9n6

 

Friday, September 16 · 1:00pm – 4:00pm

 

Visit the webchat link to:

-View the live event at 1pm EST on 9/16

-Submit your questions to the expert panel

-Read the transcript after the event

 

Presenters include the director of the National Carcinoid Foundation and people from the University of Pennsylvania.

By the numbers

(Editor’s Note: Two new items were added today to the resources page.)

While this site is about putting human faces on this disease, tonight let’s talk about numbers. They are as much a part of the story of this disease as the individuals affected by it.

The truth is that we don’t have any really reliable numbers in terms of how many people are affected by this disease.

We know that between 11,000 and 12,000 Americans were diagnosed with NEC last year. But we also know that before they were diagnosed they averaged three incorrect diagnoses. How many more die of the “side-effects” of the disease without being diagnosed, we don’t know.

We know there are about 125,000 people in the US living with this disease after having been diagnosed with it. But we do not know how many people are living with the disease without knowing they have it.

We know that in recent years diagnoses of the disease have increased by an average of five percent a year. We don’t know why.

We know that frequently, when a doctor finds a single case of NEC, he or she very quickly finds two or three more. We don’t know why.

We also know that the three drugs we have in the US treat the symptoms, but do not offer a cure–although the latest does seem to stop tumor growth in 65 percent of cases.

We know that there is a promising radiation treatment entering initial trials in Houston this year. We know that treatment has met with some success in Europe. But we also know that widespread use of the technique in this country will take years to happen.

We know that if you are rich enough–see Steve Jobs–you can go to Europe and get this treatment. But we also suspect that even that treatment will only extend life with the disease–not cure it.

We know that the National Cancer Institute alone spent more than $600,000,000 on breast cancer research last year.

We know that we spent less than $2.5 million total on NEC research last year.

We know that a lot more people will be diagnosed with breast cancer this year than will be diagnosed with NEC. But we also know the longterm prognosis for those diagnosed with breast cancer will–in most cases–be far better than the longterm prognosis for those diagnosed with NEC.

People tell me that part of the reason there is so little research done on this disease is that it is not cost-effective–that other, more frequent, forms of cancer provide more bang for the research buck–and more profits for the drug companies.

That provides little solace to the families of the thousands who die from this disease every year.

 

Why I am doing this–and a request

  • Dear friends,
    I watched my wife die last fall. I watched her world shrink from New England to Fall River to the yard to the house to a hospital room to a hospital bed. I watched her as she became so weak she could not get off the toilet unaided, as she lost control of her bowels, as she lost control of her mind.
    And all I could do was hold her hand and talk to her and be strong for her.
    In the end, it was all even her doctors could do. We simply had no real weapons to fight with.
    Jane died on December 10, 2010. The death certificate says she died of neuroendocrine cancer.
    But what really killed her was not NEC.
    What really killed her was our lack of knowledge about this little-known, frequently misdiagnosed, and chronically underfunded disease.
    Last year, the National Cancer Institute alone spent over $631 million on breast cancer, $300 million on prostate cancer, $281 million on lung cancer—nearly $5 billion in all. And those numbers do not include the millions spent by the American Cancer Society and other big cancer organizations.
    But those major groups did not spend much on neuroendocrine cancer.
    The best guess I have been able to come up with on what we spent on NEC research last year is less than $2.5 million, most of it raised by two small foundations dedicated to raising money for this one cancer.
    This summer, for the first time in 30 years, the FDA approved a new drug for NEC. That brings the total number of drugs to—three. None of those drugs offer a cure—they just relieve the symptoms somewhat—for a while.
    That needs to change.
    Jane said at one point that she wanted to be the first person to beat this disease. In the end, the only way for her to beat the cancer was to die and take it with her.
    I want this disease dead for everyone, and I don’t want them to have to die to do it.
    That’s why, on September 18, I will walk all 26 miles, 385 yards of the Boston Marathon route with the Caring for Carcinoid Foundation team for the Jimmy Fund. All the money I raise for that walk will go to support research on NEC.
    That’s why I am organizing two other projects for November 10, Neuroendocrine Tumor Awareness Day.
    It is why I started Walking with Jane.
    It is why I am asking for your support.
    Please, go to www.kintera.org/faf/donorReg/donorPledge.asp?ievent=449987&supId=331022955&msource=2011WALKFB and make a donation to support the Marathon Walk.
    Please, follow what is going on here or at facebook.com/walkingwithjane.
    Please volunteer your time and your talents.
    No one should ever have to go into this kind of battle so woefully under-armed.
    Thank you.
    Pax et lux,
    Harry

    www.kintera.org

    One in three people will face cancer in his or her lifetime, but no one has to face it alone. On Sept. 18, 2011, the participants of the Boston Marathon® Jimmy Fund Walk to benefit Dana-Farber Cancer Institute will change the odds for patients facing all forms of cancer.